Objective: Controversy exists about the treatment outcomes of the Ewing sarcoma family of tumors among low-incidence populations. We evaluated whether Korean Ewing sarcoma family of tumors patients have poorer outcomes than Euro-American patients. Methods: We retrospectively analyzed the clinicopathologic characteristics and outcomes of patients with localized Ewing sarcoma family of tumors treated at Korea Cancer Center Hospital between 1986 and 2008. Results: Seventy-six patients (48 male, 28 female) of median age 20 years (range: 1 -69 years) were evaluated. Tumors were located in central-axial parts of the body in 33 cases (43.4%) and extremity in 43 cases (56.6%). Pelvis and femur were the most frequently involved sites. Histologic response to preoperative chemotherapy was analyzed in 48 cases and there were 32 (66.7%) good responders and 16 (33.3%) poor responders. For a median follow-up of 37.9 months (range: 0.9 -260.6 months), 5-year overall survival and event-free survival rates were 58.9 + 6.1 and 52.6 + 6.1%, respectively. A poor histologic response to preoperative chemotherapy (P ¼ 0.01) and a tumor location in a central-axial body region (P ¼ 0.008) were found to be related to a poorer event-free survival. Conclusions: Survival of our Ewing sarcoma family of tumors patients was not inferior to those reported for Euro-American cases. Collaborative studies are necessary for further improvements of outcome and we believe that our data provide a basis for future studies targeting Ewing sarcoma family of tumors.
INTRODUCTION
Through multidisciplinary treatment approaches, the survival of patients with Ewing sarcoma family tumor (ESFT) has greatly improved (1) . Unfortunately, controversy exists whether the similar treatment strategies produce similar results in low-incidence populations (2 -4) . It has been reported that the treatment outcomes of ESFT in Asian, African and in Hispanic populations are poor, and this is frequently attributed to delayed diagnosis and thus, a higher proportion of patients diagnosed with advanced disease (2 -4) . And one recent study suggested that incidence and outcome differences have a genetic basis (5) . In the mean time, others have reported that survival rates in Euro-American population are similar to those in Asia, a low-incidence region (6, 7) .
The incidence of ESFT is very low in South Korea; fewer than 40 new cases are diagnosed annually (8) . Accordingly, few clinical studies have targeted ESFT patients and little data are available regarding clinical characteristics or treatment outcomes. In this retrospective study, we analyzed the outcomes of patients with localized ESFT treated at our institution and sought to answer the following questions: (i) What are the clinical characteristics of ESFT? (ii) What are its treatment outcomes and are these poorer than in Euro-American population? and (iii) What are its prognostic factors?
PATIENTS AND METHODS

PATIENTS
Between 1986 and 2008, 133 patients were registered in our ESFT database. In the present study, we retrospectively reviewed 76 selected patients who met the following criteria: (i) a new diagnosis of ESFT; (ii) localized disease; (iii) no history of prior treatment, with the exception of biopsy; (iv) treatment at our institution and (v) an event-free status over ,2 years of follow-up. The 57 exclusions were made for the following reasons: the presence of metastasis at the time of diagnosis (n ¼ 18), referral to our institute after disease relapse (n ¼ 14), prior chemotherapy or surgery at another hospital (n ¼ 9), an incorrect pathologic diagnosis (n ¼ 3) and the non-availability of clinical or follow-up data (n ¼ 13). Therefore, the final study population consisted of 76 patients. Informed consent was required from all patients and/or their legal guardians.
DIAGNOSTIC WORK-UP
ESFT was diagnosed using representative specimens obtained by open or needle biopsy and by resection. Recently, it is recommended that the diagnosis of ESFT should be based on histologic and cytogenetic analyses. However, due to the retrospective nature of this study, cytogenetic analyses were not feasible. Accordingly, diagnosis of 76 ESFT cases was solely based on immunohistochemical Jpn J Clin Oncol 2011;41(6) 777 methods-that is, the presence of small round cells, with no cytologic, histologic or immunohistochemical feature of lymphoma, rhabdomyosarcoma or neuroblastoma. To differentiate peripheral primitive neuroectodermal tumors (pPNETs) from classical Ewing sarcoma, we used the presence of neuronal differentiation and CD99 positivity. Tumor extents were evaluated by plain radiography and computed tomography (CT) or more recently, by magnetic resonance imaging (MRI). Tumor volumes were estimated by measuring the three orthogonal diameters on CT or MR images and performing the calculation described by Gö bel et al. (9) . 99m Tc-methylene diphosphonate whole-body bone scintigraphy and CT of the chest were used to determine the presence of metastases. Bone marrow examination was not routinely performed, since both marrow-positive and -negative patients alike are treated with the same chemotherapy.
TREATMENT AND FOLLOW UP OF PATIENTS WITH AN ESFT
The treatments administered to the 76 patients with ESFT were heterogeneous. Seventy-four patients (97.4%) received chemotherapy at doses and schedules that depended on era (details are provided in Table 1 ). Generally, patients received systemic chemotherapy before local tumor control was attempted. Timing for local control varied according to the chemotherapy regimen and they were: Week 9 for regimens 1 and 2, Week 6 for regimens 3 and 4-B, Week 12 for regimens 4-A and 5, and between Week 12 and 18 for regimen 6. Surgery was preferred for local tumor control, but only 65 of the 76 (85.5%) underwent surgery. Radiotherapy was performed before surgery to improve resectability in 12 cases, to achieve local control of an unresectable tumor in 6 cases or to control microscopic residual tumors after surgery in 10 cases. The median dose administered was 45.0 Gy (range: 30.0 -64.8 Gy). Histologic response to preoperative chemotherapy was evaluated using a resected tumor specimen, and were classified as follows, i.e., ,10% viable tumor cells indicating a good response, whereas those with .10% residual viable tumor indicating a poor response (10) . After local tumor control had been achieved by surgery or radiotherapy, patients underwent adjuvant chemotherapy. After completing treatments, patients were followed up for 2 years by monthly radiography of the chest and primary tumor site. CT of the chest and whole-body bone scintigraphy was performed every 3 months for 2 years. Thereafter, the same protocol was repeated every 6 months for up to 5 years and then annually.
STATISTICAL ANALYSIS
To identify prognostic factors, we searched for relations between clinicopathologic variables and survival. The clinicopathologic variables examined included age ( 12 vs. .12 years), sex, histologic subtype (Ewing sarcoma or pPNET), primary site (bone vs. soft tissue), tumor volume, tumor location (central-axial vs. extremity), treatment type (surgery, chemotherapy regimen and radiotherapy) and histologic response to preoperative chemotherapy. Cut-off value for age varied between different case series (1, 11, 12) . We have compared event-free survival (EFS) according to various cut-off age values and found that age 12 had the most significant P value. Overall survival (OS) was defined as time from diagnosis to death (due to any cause) or time to last follow-up. EFS was defined as the time from diagnosis to disease progression, local recurrence or metastasis. Survival curves were calculated using the Kaplan -Meier methods, and the log-rank test was used to examine relations between clinicopathologic variables and survival. Factors found to influence survival by univariate analysis were subjected to multivariate analysis using Cox's proportional hazard regression model, the results of which are reported as relative risks and 95% confidence intervals (CIs). All calculations were performed using SPSS version 13.0 software (SPSS Inc, Chicago, IL), and P values of , 0.05 were considered significant. cases. The primary sites were various, but the pelvis and femur were most frequently involved (Fig. 1) . Of the 48 cases analyzed with respect to histologic response, 32 (66.7%) were good responders and 16 (33.3%) were poor responders.
SURVIVAL ANALYSIS
Five-year OS and EFS rates of the 76 ESFT patients were 58.9 + 6.1 and 52.6 + 6.1%, respectively (Fig. 2) . Median follow-up duration was 37.9 months (range: 0.9 -260.6 months). There were 35 events, namely metastasis (n ¼ 19), local recurrence combined with metastasis (n ¼ 9), local recurrence (n ¼ 4) and disease progression (n ¼ 3). None of our patients developed a second new malignancy during follow up. The sites affected by metastasis were: lung (n ¼ 16), bone (n ¼ 8), lung and bone (n ¼ 2), brain (n ¼ 1) and lymph nodes (n ¼ 1 
DISCUSSION
We retrospectively analyzed the data of ESFT patients with localized disease treated at a single institution over a 20-year period. The 5-year EFS of our cohort were 52.6 + 6.1%, which was comparable with those of Euro-American studies. Local tumor control by surgery tended to improve the outcome. And histologic response to preoperative chemotherapy and tumor location (a central-axial vs. an extremity location) were found to be independently related to the survival. Our study has several limitations. First, the treatments administered, including chemotherapeutic regimens and surgical methods, varied considerably because this study was conducted over a period of 20 years. Second, ESFT was diagnosed immunohistochemically, despite recommendations that it should be based on histologic and cytogenetic analyses (13, 14) . Third, the study cohort may have been influenced by selection bias because our institute is a tertiary Jpn J Clin Oncol 2011;41 (6) 779 referral center for orthopedic oncology patients, and accordingly, cases with extremity tumors predominated in our cohort. Accordingly, we caution that our results should be applied to similar populations. We found that survival among our cohort was comparable to those reported by Bacci et al. (5-year EFS of 56.9%), the European Intergroup Cooperative Ewing's Sarcoma Study Group (5-year EFS 55%) and the St. Jude series (5-year EFS of 55.1%) (1, 11, 12) . Controversy exists about treatment outcomes of ESFT patients from low-incidence populations (2 -4,15) . And in particular, it has been reported that Asian, African and Hispanic ESFT patients show poorer outcomes, even when treated with the same protocols as those of Euro-American patients (16) . In the Japanese Musculoskeletal Oncology Group Cooperative Study, the EFS of patients with localized disease was 46.6%, but recent clinical outcomes of patients treated with a chemotherapy regimen including ifosfamide and etoposide were comparable to those reported by the Euro-American studies (6, 7) . It remains unproved that whether a poor treatment outcome among low-incidence populations is the result of differences in access to healthcare systems or to a lack of multiinstitutional studies. Because the clinical trial conducted by the Children's Oncology Group found a better outcome than previously published data, we presume that a prospective multicenter trial would result in a further improvement in the outcome of our ESFT patients (17) . However, studies on the biology and genetic characteristics of ESFT are also needed. A recent study showed that the incidence of genomic instability at chromosome 19 was greater in Japanese ESFT 780 Treatment outcome of Korean ESFT patients cases than in German cases (16) . Accordingly, studies are needed to elucidate whether genetic or biologic differences between ethnic groups can explain the differences between the incidence and clinical behavior of ESFT. The present study shows that tumor location is an independent prognostic factor. The prognostic importance of tumor location has been previously reported (11, 12) . Usually, centrally located tumors are diagnosed later than those located in the extremities, and accordingly, are larger at diagnosis. Furthermore, local control by surgery might be challenging due to anatomic or functional defects associated with curative surgery. The importance of surgery in the treatment of ESFT is supported by previous clinical studies, which indicated that surgical technique developments are associated with outcome improvements (18) . Unfortunately, we could not analyze the prognostic impact of surgical margins, due to the limited information. We presumed that the surgical margins might be 'wide', unless the cases underwent radiotherapy after surgery or pathologically 'resection margin positive for tumor cells'. The influence of surgical margins needs to be evaluated in future studies.
A more intensified chemotherapy might improve the histologic response, as well as survival of Korean patients with localized ESFT. As has been reported previously, we found that the histologic response to preoperative chemotherapy is an important prognostic factor (19, 20) . However, response to chemotherapy seems to be related to the chemotherapy regimen. Thirty-two of our cases (66.7%) were good responders, and the proportion of good responders was greater in cases treated with a more intensive regimen. For example, 12 patients (42.9%) treated with regimen 3/4-B were good responders, while all 14 (100%) treated with intensified regimen 4-A were good responders. And improved histologic response on regimen 4-A tended to be related to a better EFS, although this improvement was statistically not significant (P ¼ 0.27). In addition to increasing the proportion of good responders, we believe that a more intensive chemotherapy regimen might further improve the survival. Furthermore, we have found a trend toward better survival among patients that were treated with five-agent regimen (5-year EFS 70.0 + 18.2% for regimen 5) when compared with those treated with a two-agent regimen (58.0 + 7.4% for regimens 3/4-A and 4-B). Surmising from these data, the treatment outcome of our ESFT patients might be further improved with more intensified chemotherapy, and welldesigned multi-center clinical trial is a prerequisite.
In conclusion, we found that the survival of our ESFT patients achieved over the last 20 years was not inferior to those reported in major series of Euro-American studies. Furthermore, the prognostic factors identified in the present study, namely tumor location and histologic response to preoperative chemotherapy, were also similar. In addition to adding to our understanding of clinical characteristics of Korean ESFT cases, our data can be used as the basis for establishing an effective therapy for ESFT. We believe that the outcome of ESFT patients among low-incidence population might be improved with a prospective multicenter trial. Also, further studies are required to elucidate the biologic, genetic and environmental differences of ESFT.
